Author: Nicole Wetsman
Photo by Blake Nissen for The Boston Globe via Getty Images
Moderna plans to file for authorization of its COVID-19 vaccine today, after the final analysis of its clinical trial data confirmed that it is safe and 94 percent effective. It is the second company to submit COVID-19 vaccine data to the Food and Drug Administration, after Pfizer and BioNTech submitted their data earlier this month.
In a press release, Moderna said that there were 196 cases of symptomatic COVID-19 reported in the 30,000-person trial. Of those cases, 185 developed in people who received a placebo, and 11 cases developed in people who took the vaccine. There were 30 cases of severe disease in the trial, and all of them were in the placebo group — indicating that the vaccine can prevent the most dangerous forms of...
Continue reading…
Continue reading...
Photo by Blake Nissen for The Boston Globe via Getty Images
Moderna plans to file for authorization of its COVID-19 vaccine today, after the final analysis of its clinical trial data confirmed that it is safe and 94 percent effective. It is the second company to submit COVID-19 vaccine data to the Food and Drug Administration, after Pfizer and BioNTech submitted their data earlier this month.
In a press release, Moderna said that there were 196 cases of symptomatic COVID-19 reported in the 30,000-person trial. Of those cases, 185 developed in people who received a placebo, and 11 cases developed in people who took the vaccine. There were 30 cases of severe disease in the trial, and all of them were in the placebo group — indicating that the vaccine can prevent the most dangerous forms of...
Continue reading…
Continue reading...